uniQure (QURE) Insider Madhavan Balachandran Sells 10,000 Shares

Madhavan Balachandran sold 10,000 shares of uniQure N.V. (NASDAQ: QURE) on June 15, 2026. This transaction is valued at around $481,600, based on the last closing price of $48.16. Balachandran's sale adds to the recent activity among insiders at the company as they adjust their holdings.

Inside Madhavan Balachandran's Trade

Balachandran's recent sale of 10,000 shares reflects his ongoing strategy in managing his stake in uniQure. This sale comes after several insider transactions, including a notable purchase by CEO Matthew Kapusta just days prior. The trade indicates a response to market conditions and personal financial management, rather than a negative outlook on the company's performance.

Other Institutional Activity in uniQure

Several institutional investors have recently adjusted their stakes in uniQure. Avoro Capital Advisors LLC increased its holdings by 768,191 shares, bringing its total to 6,727,777 shares worth approximately $148 million. JPMorgan Chase & Co. added 2,030,241 shares to reach 4,867,755 shares valued at about $107 million. RTW Investments LP raised its position by 1,355,239 shares, totaling 3,941,572 shares worth around $87 million. State Street Corporation also grew its holdings by 643,335 shares, ending with 2,903,825 shares valued at approximately $63.9 million. In contrast, Aberdeen Group plc reduced its stake by 2,458,604 shares, leaving it with 2,848,117 shares worth about $62.7 million.

uniQure N.V. Stock Up 129.7%

uniQure's shares have shown strong performance, trading at $48.16, significantly above its 52-week low of $8.73 and closer to its recent highs. The stock's movement suggests growing investor confidence in the company's future, especially in light of its upcoming earnings report scheduled for November 9, 2026.

Recent Earnings

uniQure reported revenue of $18.7 million for the latest quarter, reflecting a growth rate of 11%. However, the company faced a net loss with an EPS of -$4.03. The next earnings report, set for November 9, will likely shed light on its ongoing projects and financial health.

Insider Buying and Selling at uniQure N.V.

In addition to Balachandran's sale, other insiders have also been active. On June 26, Chief Medical Officer Walid Abi-Saab sold 1,434 shares at an average price of $46.86, totaling about $67,197. Meanwhile, CEO Matthew Kapusta has been actively buying shares, including a purchase of 4,128 shares at $31.71 on June 24, worth approximately $130,899, and a planned sale of 6,696 shares at $50 each.

Analysts Set New Price Targets

Analysts have recently adjusted their outlook on uniQure. On October 5, Barclays downgraded the stock to an Equal-Weight rating with a target of $28, down from $60. RBC Capital maintained its Outperform rating with a target of $48, reduced from $65. Meanwhile, Goldman Sachs kept its Neutral rating with a target of $31, down from $46. Wells Fargo maintained its Overweight rating and raised its target to $75 from $60. Wolfe Research upgraded the stock to Outperform, setting a target of $65.

About uniQure

uniQure N.V. develops innovative treatments for patients with rare diseases. The company's key products include HEMGENIX, which helps those with hemophilia B, and AMT-130, a gene therapy currently in clinical trials for Huntington's disease. With 221 employees based in Amsterdam, the company continues to focus on advancing its pipeline amid a competitive biotech landscape.

Bottom Line

Investors should keep an eye on upcoming earnings on November 9 for insight into uniQure's financial performance and potential market strategies. Insider trading activity shows mixed signals, but the overall analyst consensus remains positive. The recent 13F filings indicate a dynamic trading environment that could influence share movements in the near future.